Case reports have demonstrated that MEK inhibitors such as trametinib and BRAF inhibitors such as vemurafenib can be effective in HS patients harboring MAPK/ERK pathway mutations [10], including BRAF V600E [11], KRAS [12], and MAP2K1 [13,14]. This evidence concerns the gene MAP2K7 and histiocytic sarcoma.